Globus Medical, Inc. (GMED) Stock Price & How to Invest

Last updated November 2026

Short answer

You can invest in Globus Medical (GMED) by buying shares or fractional shares at any major broker, through a medical-device or healthcare-equipment ETF that holds it, or as one holding in a thematic basket built around surgical robotics. Globus is the number two player in global spine surgery after the 2023 NuVasive merger, and the thing to understand is that it sells implants and instruments first and robots second: the ExcelsiusGPS robot is largely a channel for pulling higher-margin implant volume into Globus-equipped operating rooms.

GMED stock price

As of 2026-11-16, Globus Medical, Inc. (GMED) last closed at $70.50, down 15.7% over the past year. Over the past 52 weeks it has traded between $70.50 and $96.82.

GMED last close
$70.50
1 day
-2.27%
1 month
-8.10%
1 year
-15.71%
52-week range
$70.50 to $96.82
Last close
2026-11-16

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Globus Medical, Inc.'s investor relations page. Walnut is informational, not investment advice.

GMED key stats

At $70.50 on November 16, 2026, Globus Medical, Inc. (GMED) has a market cap of $9.4B and a P/E of 17.4 on trailing earnings (13.2 on forward earnings).

Market cap
$9.4B
P/E (trailing)
17.4
P/E (forward)
13.2
EPS (trailing 12 months)
$4.06
Price to book
2.0
Beta
0.95

Market cap, P/E and yield are measured at the $70.50 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Globus Medical, Inc. (GMED)?

The last two weeks for Globus Medical, Inc., as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • GMED closed at $70.50 on November 16, 2026, down 7.7% over the past five trading days (from $76.37).
  • On November 5, 2026, Globus Medical, Inc. filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
  • On November 5, 2026, Globus Medical, Inc. filed an 8-K with the SEC reporting quarterly results and other events (Item 2.02, Item 8.01). Read the 8-K on sec.gov
  • On November 9, 2026, Truist Securities lowered its target to $90.00 from $100.00 (Buy).
  • On November 6, 2026, Canaccord Genuity lowered its target to $105.00 from $115.00 (Buy).
  • On November 6, 2026, Wells Fargo raised its target to $100.00 from $99.00 (Overweight).

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

Globus Medical, Inc. (GMED) latest quarter

Globus Medical reported revenue of $764 million for Q3 2026, down 1% from a year earlier (Globus Medical, Nov 5, 2026).

Revenue
$764 million
down 1% from a year earlier
Diluted EPS (GAAP)
$1.04
up 18% from a year earlier
Musculoskeletal Solutions
$729 million
down 2% from a year earlier

Source: Globus Medical Q3 2026 results, Nov 5, 2026. Full earnings breakdown

What does Globus Medical, Inc. (GMED) do?

Globus Medical designs and sells musculoskeletal implants and the enabling technology used to place them. The core business is spine: pedicle screws, interbody cages, cervical plates, expandable implants and the disposable instruments that go with them, sold to hospitals and surgery centers largely through a direct sales force. Sitting on top of that is the enabling-technology line, principally the ExcelsiusGPS robotic navigation platform, the Excelsius3D imaging system and the Excelsius Flex robot aimed at knee replacement. The robots themselves are a modest share of revenue; their commercial purpose is to place capital in a hospital and pull recurring implant volume through it for years afterward. The September 2023 all-stock merger with NuVasive roughly doubled the company's size and made it the second largest spine business in the world behind Medtronic, and the April 2025 acquisition of Nevro added spinal cord stimulation for chronic pain, extending Globus beyond surgical implants into neuromodulation.

The investment picture in October 2026 is mostly about integration paying off. Q2 2026 revenue was about $789.6 million, up roughly 6% as reported and around 9% excluding Nevro, with US Spine up about 7% (a fifth straight quarter the company describes as above-market) and international spine up about 14%. The margin story is the sharper one: adjusted EBITDA margin reached roughly 35.4%, an expansion of about 740 basis points year over year, and non-GAAP EPS of about $1.34 grew roughly 56%. Management reaffirmed full-year revenue guidance of about $3.18 billion to $3.22 billion and raised non-GAAP EPS guidance to roughly $4.95 to $5.05 from $4.70 to $4.80. Against that, Nevro sales fell about 14% year over year and management does not expect trial volumes to recover until late in Q4 2026, and a July 2024 FDA warning letter concerning complaint handling and adverse-event reporting for ExcelsiusGPS remains part of the backdrop.

The Q2 print extended a run of four straight quarters of non-GAAP EPS above consensus (the $1.34 compared with an estimate of about $1.10). The stock has not followed the earnings: as of October 16, 2026 GMED closed near $77.94, down about 11% year to date though still up about 33% over the past year, for a market value of roughly $10.5 billion. Globus reports Q3 2026 results on November 5, 2026, with consensus looking for non-GAAP EPS of about $1.20 on roughly $792 million of revenue, which would be revenue growth of only a few percent while Nevro remains a drag.

What's driving Globus Medical, Inc. (GMED)?

1. NuVasive integration and operating leverage.

The merger's promised cost synergies are now showing up in reported numbers rather than slides, with adjusted EBITDA margin near 35% and non-GAAP EPS growing several times faster than revenue. Combining two direct sales forces, consolidating manufacturing and rationalizing overlapping implant lines is the mechanism. How much further this runs is the main swing factor in the next few years of earnings, because the revenue growth rate alone does not explain the EPS growth rate.

2. Robotics as an implant channel.

ExcelsiusGPS placements matter less for the capital revenue they generate than for the implant pull-through that follows, since a hospital that installs a Globus robot tends to standardize on Globus screws and cages. Excelsius3D imaging and the Excelsius Flex knee robot extend the same logic into imaging and orthopedics, where Stryker's Mako already set the pattern. The installed base is effectively a switching-cost asset, and its growth rate is a better leading indicator of future implant share than any single quarter's revenue.

3. Competitive recruiting and international expansion.

Globus attributes much of its above-market US spine growth to recruiting surgeons and distributors away from rivals, which is a repeatable but not infinite lever. International spine grew about 14% in Q2 2026 with double-digit gains across EMEA, APAC and Latin America, off a smaller base than the US and with more room left. The NuVasive combination gave the company a broader international footprint than either had alone.

4. Neuromodulation via Nevro.

The Nevro acquisition brought high-frequency spinal cord stimulation for chronic pain, a market adjacent to spine surgery and served by the same physicians. It is currently a drag: sales fell about 14% year over year in Q2 2026, and management points to late Q4 2026 before trial volumes recover. Whether Globus's larger sales channel can stabilize a franchise that was losing share before the deal is an open question, and the answer determines whether this becomes a growth line or a written-down one.

5. Q3 2026 results on November 5.

Consensus for the third quarter is non-GAAP EPS of about $1.20 on revenue of about $792 million, against $1.18 a year earlier, so expectations assume margins hold while revenue growth slows. Globus has beaten the EPS estimate in each of the last four quarters, by margins ranging from about $0.13 to $0.40. The report will also update whether Nevro trial volumes are on the path management laid out for a late Q4 2026 recovery.

What are the risks to Globus Medical, Inc. (GMED)?

The largest structural risk is pricing: spinal implants face steady per-unit price erosion from hospital purchasing groups and payers, so Globus has to grow procedure volume just to hold revenue flat. Competition is heavy on both flanks, with Medtronic and its Mazor platform on one side and fast-growing challengers such as Alphatec taking surgeon share on the other, and the surgeon-recruiting lever that drives current outperformance can run in reverse. Regulatory exposure is concrete rather than theoretical: the July 2024 FDA warning letter concerning ExcelsiusGPS complaint handling and medical device reporting is the kind of matter that can escalate to consent decrees or shipment holds if not resolved. Nevro is shrinking, and management's own recovery timeline extends into late 2026, so an impairment is possible if trial volumes stay weak. Plaintiff firms have publicly announced investigations following the 2025 revenue miss and the FDA letter, and product-liability activity around spinal cord stimulators adds separate legal cost that is hard to size in advance.

What is the Globus Medical, Inc. (GMED) forecast?

14 analysts publish price targets on GMED, averaging $93.43 as of November 2026, or +32.5% against the $70.50 share price on November 16, 2026. The published targets run from $75.00 to $110.00, a moderate spread, and the ratings split 10 buy, 5 hold, 0 sell. Over the last six months there has been 1 raise and 9 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full GMED forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is GMED a buy or a sell?

We give no verdict on Globus Medical, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. NuVasive integration and operating leverage. The merger's promised cost synergies are now showing up in reported numbers rather than slides, with adjusted EBITDA margin near 35% and non-GAAP EPS growing several times faster than revenue. The most optimistic published target, $110.00, assumes this works close to its best case.

The case against. The largest structural risk is pricing: spinal implants face steady per-unit price erosion from hospital purchasing groups and payers, so Globus has to grow procedure volume just to hold revenue flat. The most pessimistic target, $75.00, is roughly what GMED is worth if this bites instead.

Read the full bull and bear case on GMED, including what would have to change to break either one. Walnut is not an investment adviser.

Has Globus Medical, Inc. (GMED) split its stock?

No. Globus Medical, Inc. (GMED) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is Globus Medical, Inc. (GMED) valued?

Market cap, P/E and dividend yield at today's price are in the GMED key stats above. The business figures below come from Globus Medical, Inc.'s reported results as of October 2026 and change when it next reports.

  • Revenue (TTM): ~$3.14 billion
  • Q2 2026 revenue: ~$789.6 million, up ~6% year over year (~9% excluding Nevro)
  • Margins (TTM): ~69% gross, ~25% operating, ~17% net
  • FY2026 guidance: Revenue ~$3.18 to ~$3.22 billion; non-GAAP EPS raised to ~$4.95 to ~$5.05

As of October 2026: At roughly $77.94 a share against 2026 consensus non-GAAP EPS of about $5.00 and 2027 consensus near $5.40, Globus trades around 14 to 16 times forward earnings and about 3.3 times trailing revenue, a discount to large-cap medtech peers. The shares have fallen about 11% in 2026 despite four consecutive earnings beats, which suggests the market is discounting slowing revenue growth and the Nevro drag more than it is rewarding margin expansion. The balance sheet is light, with about $595 million of cash against roughly $112 million of debt.

Who competes with Globus Medical, Inc. (GMED)?

Large diversified medtech

Medtronic is the number one spine company globally and owns the Mazor X robotic platform, making it the direct benchmark for both implants and enabling technology. Johnson & Johnson MedTech (DePuy Synthes) and Stryker also compete across spine, and Stryker's Mako franchise sets the standard in robotic joint replacement that Excelsius Flex is targeting. These firms can subsidize spine pricing from other divisions in a way a spine-concentrated company cannot.

Focused spine challengers

Alphatec (ATEC) has grown well above market by recruiting surgeons with a procedure-focused approach, taking share from exactly the accounts Globus competes for, and Orthofix (which absorbed SeaSpine) plays in the same space. These are smaller than Globus but nimble on pricing and surgeon relationships, and they are the main source of the share shifts that show up in Globus's quarterly US spine numbers.

Neuromodulation incumbents

Through Nevro, Globus now competes in spinal cord stimulation against Boston Scientific, Abbott and Medtronic, all of which have larger neuromodulation franchises, deeper physician relationships and more clinical evidence behind their platforms. Nevro was losing share to this group before the acquisition, which is the context for its continuing revenue decline.

What stocks are similar to Globus Medical, Inc. (GMED)?

Other names that sit close to GMED: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Globus Medical, Inc. (GMED)

There are three common ways to get GMED exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so GMED sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where GMED fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Globus Medical, Inc. (GMED)

As of October 2026, Globus Medical is a scaled spine-implant business using robotics as a distribution wedge, converting the NuVasive integration into real margin expansion, with the stock down about 11% in 2026 and trading near 14x forward earnings; the open questions are whether above-market spine growth holds and whether the Nevro neuromodulation acquisition stops shrinking.

More on Globus Medical, Inc. (GMED)

Whether GMED is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is GMED a buy or a sell?, and where the stock could go from here in the GMED stock forecast.

For income investors, whether GMED pays a dividend and how the payout looks is covered in does GMED pay a dividend? And to weigh GMED against a peer, read the full side-by-side comparisons: GMED vs MDT and GMED vs JNJ.

Wondering how GMED fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Globus Medical, Inc.

Ask Walnut's AI anything about GMED and see how it fits what you own.

FAQ

What does Globus Medical actually sell?

+

Mostly spinal implants and the instruments used to place them: pedicle screws, interbody cages, cervical plates and expandable devices, sold to hospitals and surgery centers through a largely direct sales force. On top of that sits enabling technology, principally the ExcelsiusGPS robotic navigation system, Excelsius3D imaging and the Excelsius Flex knee robot. Since April 2025 it also sells Nevro spinal cord stimulators for chronic pain. Implants and disposables, not robots, generate the large majority of revenue.

Is Globus Medical a robotics company or an implant company?

+

An implant company that uses robotics commercially. Robot capital sales are a small slice of revenue; the strategic value of an ExcelsiusGPS placement is that the hospital then standardizes on Globus implants for the procedures done on it. That makes the installed base a distribution asset with switching costs attached, which is why the company reports enabling-technology placements as a leading indicator rather than as a profit center in its own right.

How did the NuVasive merger change the company?

+

The all-stock merger closed in September 2023 and roughly doubled Globus's revenue, making it the second largest spine company in the world behind Medtronic and giving it a much larger international footprint. The financial payoff has come more through cost synergies than through revenue: Q2 2026 adjusted EBITDA margin of about 35.4% was up roughly 740 basis points year over year while revenue grew about 6%. Merger amortization is also why GAAP and non-GAAP earnings differ so widely.

Why did Globus buy Nevro, and how is it going?

+

Nevro brought high-frequency spinal cord stimulation for chronic pain, an adjacent market treated by many of the same physicians, acquired in April 2025 at a heavily discounted valuation after Nevro had been losing share. So far it is a drag rather than a driver: Q2 2026 Nevro sales fell about 14.3% year over year, and management expects trial volumes to recover only by late Q4 2026. This is why Globus reports base-business growth excluding Nevro alongside the reported figure.

What is the FDA warning letter about?

+

In July 2024 the FDA issued Globus a warning letter following an early-2024 inspection of its Audubon, Pennsylvania facilities, citing deficiencies in complaint handling procedures and in medical device reporting for the ExcelsiusGPS robotic system, including the investigation of misplaced-screw complaints and the timeliness of serious-injury reports. Warning letters are a compliance matter rather than a product recall, but unresolved ones can escalate, and this one has been cited in plaintiff-firm investigations of the stock.

How does Globus Medical make money if implant prices keep falling?

+

Spinal implant pricing erodes a few percent a year under hospital purchasing-group pressure, so revenue growth has to come from procedure volume and share gains. Globus's stated levers are competitive recruiting of surgeons and distributors, new product launches, international expansion (up about 14% in Q2 2026) and pulling implant volume through robot placements. Margin, meanwhile, has been driven by merger cost synergies rather than price.

How is GMED valued compared with other medtech stocks?

+

At about $77.94 a share in October 2026 against 2026 consensus non-GAAP EPS of roughly $5.00, Globus trades near 16 times this year's adjusted earnings and about 14 times 2027 estimates, with a market capitalization of about $10.5 billion on trailing revenue of about $3.14 billion. That is a discount to the multiples typically carried by large-cap medtech, a gap tied to the market's view of spine as a slower-growth, price-pressured category. The trailing GAAP P/E is about 20 times because merger amortization is excluded from the adjusted figures.

How can I hold GMED alongside other surgical-robotics or medtech names?

+

GMED trades on the NYSE and can be bought in whole or fractional shares at any major broker, or held indirectly through healthcare-equipment and medical-device ETFs. In Walnut, a common structure is to put it in a thematic basket next to other enabling-technology and orthopedics names such as Intuitive Surgical, Stryker or Medtronic, with target weights set in advance so no single position drifts to dominate. Grouping it that way makes it clearer whether returns are coming from the robotics theme or from company-specific execution.

How did Globus Medical do in its latest quarter?

+

In Q2 2026 revenue was about $789.6 million, up roughly 6% (about 9% excluding Nevro), and non-GAAP EPS of about $1.34 beat the consensus of roughly $1.10 and grew about 56%. Adjusted EBITDA margin expanded to about 35.4%, and management raised full-year non-GAAP EPS guidance to about $4.95 to $5.05. The next report is due November 5, 2026, with consensus at about $1.20 of EPS.

How has GMED stock performed in 2026?

+

As of October 16, 2026 GMED closed near $77.94, down about 11% year to date but up about 33% over the past year, with a 52-week range of roughly $58.51 to $101.40. The decline this year came even as the company beat earnings estimates each quarter. The 13 analysts tracked by Yahoo Finance have a mean price target of about $101. Walnut is not an investment adviser.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Globus Medical, Inc.'s investor relations page or your broker before making investment decisions.